Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Steve N. Slilaty Insider Profile
4 Followers
Steve N. Slilaty, CEO, Director, Ten Percent Owner at Sunshine Biopharma, holds 30.00K shares in Sunshine Biopharma (Ticker: SBFM). Most recently, Steve N. Slilaty Bought $20,000 shares of Sunshine Biopharma on Feb 12, 2024 for an estimated value of 2.00K.
Steve N. Slilaty has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of Steve N. Slilaty's holdings
Insider Roles
CEO, Director, Ten Percent Owner
Roles that Steve N. Slilaty holds in companies
Most Profitable Insider Trade
The most profitable trade made by Steve N. Slilaty
Steve N. Slilaty's Trading History
List of latest transactions for each holding click on a transaction to see Steve N. Slilaty's performance on stock
You May Also Like
Steve N. Slilaty insider profile FAQ
What is the percentage of profitable transactions made by Steve N. Slilaty?
The percentage of profitable transactions made by Steve N. Slilaty is ―.
What is the average return per transaction made by Steve N. Slilaty?
The average return per transaction made by Steve N. Slilaty is ―.
What stocks does Steve N. Slilaty hold?
Steve N. Slilaty holds: SBFM stocks.
What was Steve N. Slilaty’s latest transaction?
Steve N. Slilaty latest transaction was an Informative Buy of $2.00K.
What was Steve N. Slilaty's most profitable transaction?
Steve N. Slilaty’s most profitable transaction was an Informative Buy of SBFM stock on February 12, 2024. The return on the trade was -99.20%.
What is Steve N. Slilaty's role in Sunshine Biopharma?
Steve N. Slilaty's role in Sunshine Biopharma is CEO, Director, Ten Percent Owner.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.